Prognostic impact of highly active antiretroviral therapy in HIV-related Hodgkin's disease.

To evaluate the influence of highly active antiretroviral therapy (HAART) on the outcome of HIV-related Hodgkin's disease (HD), two groups were studied: patients without previous HAART, and patients treated with HAART previously or concomitantly with HD therapy. In the second group, the complete response was higher and the disease-free survival and overall survival probabilities were significantly longer. HAART is thus associated with an improvement in response to therapy and survival in patients with HIV-related HD.

[1]  J. Mate,et al.  Favorable Impact of Virological Response to Highly Active Antiretroviral Therapy on Survival in Patients with AIDS-related Lymphoma , 2002, Leukemia & lymphoma.

[2]  F. Facchetti,et al.  Hodgkin disease developing in patients infected by human immunodeficiency virus results in clinical features and a prognosis similar to those in patients with human immunodeficiency virus‐related non‐Hodgkin lymphoma , 2001, Cancer.

[3]  H. Stellbrink,et al.  Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery , 2001, AIDS.

[4]  L. Larocca,et al.  Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy , 2001, AIDS.

[5]  U. Tirelli,et al.  Impact of HAART on the clinical management of AIDS-related cancers. , 2001, European journal of cancer.

[6]  L. Grochow,et al.  Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Goedert,et al.  Association of cancer with AIDS-related immunosuppression in adults. , 2001, JAMA.

[8]  J. Romeu,et al.  Influence of highly active anti‐retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome‐related non‐Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone , 2001, British journal of haematology.

[9]  R. Talamini,et al.  Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus‐related, non‐Hodgkin lymphoma , 2001, Cancer.

[10]  U. Tirelli,et al.  Human immunodeficiency virus-associated Hodgkin's disease. , 2000, Seminars in oncology.

[11]  B. Ledergerber,et al.  HIV-associated non-Hodgkin's lymphoma: highly active antiretroviral therapy improves remission rate of chemotherapy. , 1999, AIDS.

[12]  J. Armitage,et al.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  S. Franceschi,et al.  Hodgkin's disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  H Stein,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[15]  M Tubiana,et al.  Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.